Healthcare: Never Will I Ever Buy Pre-Clinical Biotech Stocks. No Way!

<p>Only 10% of drugs make it across the FDA finish line from phase 1 clinical trials, making acquiring pre-clinical biotech stocks the riskiest game in town.</p>